Newspaper Publication - The extract of Audited Standalone and Consolidated Financial Results for the Quarter and Financial year ended on March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivanza Biosciences has published its audited financial results for Q4 FY25 and full year FY25 in Indian Express (English) and Financial Express (Gujarati), as required under SEBI Listing Regulations. On a consolidated basis, full-year revenue from operations fell sharply to Rs. 748.48 lakhs from Rs. 2,788.91 lakhs in FY24, a drop of about 73%. The company swung to a consolidated net loss of Rs. 67.41 lakhs for FY25, compared to a net profit of Rs. 54.73 lakhs in FY24. Standalone results were weaker too, with FY25 revenue of Rs. 297.74 lakhs (vs Rs. 1,446.73 lakhs in FY24) and a standalone net loss of Rs. 69.51 lakhs against a profit of Rs. 31.74 lakhs last year. EPS for FY25 stood at Rs. (0.17) versus Rs. 0.14 in FY24.
Shareholders should note a significant deterioration in business: revenue nearly halved on a standalone basis and the company moved from profit to loss at both levels. This weak performance could weigh negatively on investor sentiment and the stock price in the near term.